SciClone Pharmaceuticals : Voluntary Announcement - Formation of the Strategic Cooperation with SF Pharmaceuticals to Create One-Stop F2C Supply Chain Solution in the Field of Life and Health

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE

Formation of the Strategic Cooperation with SF Pharmaceuticals

to Create One-Stop F2C Supply Chain Solution

in the Field of Life and Health

This announcement is made by SciClone Pharmaceuticals (Holdings) Limited (the "Company" or "SciClone Pharmaceuticals", together with its subsidiaries, the "Group") on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed on the latest business plans and development of the Group.

The Company is pleased to announce the formal start of strategic cooperation with Shanghai SF Pharmaceuticals Supply Chain Holdings Co., Ltd. ("SF Pharmaceuticals"), as a certified supply chain service provider of the Company. Both parties will work together to build a one-stop supply chain solution from F-end life and health enterprise to C-end patient users. The Company will further deepen and develop its Go-To-Patient ("GTP") innovative business model, provide patients with professional, safe and reliable full-processend-to-end services, and build a higher standard for the F2C supply chain in China's field of life and health.

Relying on the innovative business model of full-chain information visualization of SF Pharmaceuticals, the Company will deepen and expand its GTP platform

The Company's innovative GTP model extends the sales of prescription drugs beyond hospitals into pharmacies, enhancing drugs' accessibility to patients and realizing the diversification of distribution channels and the maximum coverage of patients. Patients can consult offline and upload their prescriptions after registering on the Immunology Online portal, enabling online order and delivery or offline purchase and collection of drugs from DTP pharmacies.

1

The Company recognizes SF Pharmaceuticals' supply chain adaptation and responsiveness in the field of life and health, its digitalization in manpower, productivity and operation, and its ability to visualize end-to-end. The certification and strategic cooperation of service provider mark the establishment of the F2C supply chain industry standard system in the life and health field, and will further deepen and develop the GTP model of the Company, expanding the coverage of patients and improving the efficiency of service for patients and the assurance of product quality. Through this cooperation, both parties will realize: end-to-endC-end direct access logistics, warehouse nearby delivery, and improvement of the efficiency of the supply chain; the whole-process data service to obtain the truest flow direction data, so as to reasonably manage existing customers and incremental customers; provision of management support for targeted product flow channel, and accurate and true discovery of the product flow that violates the channel management requirements; and provision of professional temperature and humidity guarantee and information tracing throughout the process, to enable patients to access secure pharmaceutical services.

Through this service certification for SF's supply chain and the opportunity of strategic cooperation, the Company will gain benefit to continue to expand the GTP model and provide patients with highly efficient, professional, safe and reliable medical and health services.

The Company may or may not be able to further expand the sales on GTP platform through this strategic cooperation. Shareholders and potential investors of the Company are advised to exercise caution in dealing in shares of the Company.

About Sciclone Pharmaceuticals:

The Company is a biopharmaceutical company with an integrated platform for product development and commercialization. The Company strategically focuses on some of the largest and fast-growing therapeutic areas with significant unmet medical needs in China, primarily including oncology and severe infection. With its product development and commercialization strength, the Company has established a good track record in terms of balanced and high-quality products on the market in key therapeutic areas and in developing and commercializing portfolios of pipeline products with better potential.

For more information about the Company, please visit: www.sciclone.com.

2

About SF Pharmaceuticals:

As a wholly-owned subsidiary of SF Group (a company listed on the Shenzhen Stock Exchange, Stock Code: 002352), SF Pharmaceuticals, relying on SF Group's advanced experience in supply chain service management, optimization and quick responsiveness, is committed to providing "C-end direct access, cold chain support, efficient warehouse allocation and whole-process visibility, safe and reliable" third-party services for drug manufacturers, distribution enterprises, vaccine manufacturers, disease control centres at all levels, hospitals and chain pharmacies and other customers in the field of life and health, and enables end users to access better, safer, more efficient and more accessible medical services.

Definitions

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

"DTP pharmacies"	direct-to-patient pharmacies, which refer to pharmacies that directly
	provide valuable professional services to patients. When patients receive
	doctor prescriptions from the hospitals, DTP pharmacies deliver the drugs
	to the patients based on their prescriptions at the time and location of
	patients' choices.
"F2C"	a factory-to-customere-commerce model. The factory will directly
	sell and deliver the products to customers after its production through
	logistics service.

By order of the Board

SciClone Pharmaceuticals (Holdings) Limited

ZHAO Hong

Executive Director, Chief Executive Officer and President

Hong Kong, 23 April 2021

As at the date of this announcement, the board of directors comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Xiaozhuo as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

*  for identification purpose only

3